Lupin eyes $500 million from biosimilars, expands global footprint
NiveshIQ
NSE: LUPIN · Pharma
Lupin Ltd.
₹2,095.00▲ ₹17.20 (+0.83%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on LUPIN. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Lupin Ltd.
Lupin Limited is a leading Indian pharmaceutical company operating in the Pharmaceuticals and Others segments. The company produces and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) across therapeutic areas. Lupin's revenue drivers include its strong presence in the US market, where it generates a significant portion of its sales. The company has recently received USFDA approval for its Diazepam injection, targeting a US$77.9 million market. Lupin's diversified product portfolio, coupled with its expanding presence in the US, positions it for growth. The company's recent financial performance, with revenue of ₹27,958 crore and net income of ₹5,333 crore, is a testament to its operational efficiency. With a strong trac
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹20,011 Cr +128.60% | ₹22,708 Cr +13.50% | ₹27,046 Cr +19.10% |
| EBITDA Margin | 19.03% | 23.15% | 32.03% |
| Net Profit | ₹1,935 Cr +383.80% | ₹3,306 Cr +70.90% | ₹5,324 Cr +61.00% |
| EPS | ₹42.06 | ₹71.93 | ₹111.00 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Lupin Part 4 Trailer : Omar Sy and Ludivine Sagnier Starrer Lupin Part 4 Official Trailer
Lupin eyes $500 mn biosimilars revenue in medium term, to ramp capacity
🔒
+ 3 more stories about Lupin Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹8, 277 Cr, PAT ₹1, 417 Cr, EPS ₹30.95, EBITDA margin 31.2%. Growth context: revenue QoQ +10.7%, PAT QoQ -3.5%. Street verdict: beat, revenue surprise +4.6%, PAT surprise +7.1%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and new product launches a...
FY26 (last completed FY): revenue ₹27, 046 Cr, PAT ₹5, 324 Cr, EBITDA margin 32.0%, EPS ₹111.00. Year-on-year: revenue Y...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for LUPIN
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track LUPIN alongside your other holdings
Unlock full LUPIN research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Lupin Ltd.?
NiveshIQ detects active intelligence signals for Lupin Ltd. (LUPIN) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Lupin Ltd.?
Lupin Ltd. operates in the Pharma sector with a market capitalisation of ₹10,321,566.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.